A new experimental drug for pancreatic cancer, based on university research, is showing promising results in clinical trials. The drug may potentially increase survival time for patients with one of the deadliest forms of cancer, with some reports suggesting it nearly doubles survival time. The exact nature and extent of the drug's effectiveness are still being studied and reported by various medical institutions.